Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells 25,592 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 25,592 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total transaction of $90,339.76. Following the completion of the sale, the chief executive officer directly owned 7,202,481 shares of the company's stock, valued at approximately $25,424,757.93. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Puma Biotechnology Stock Performance

Shares of Puma Biotechnology stock traded down $0.13 on Friday, hitting $3.39. 300,719 shares of the company's stock were exchanged, compared to its average volume of 414,487. The company has a 50-day simple moving average of $3.37 and a 200-day simple moving average of $3.18. The stock has a market capitalization of $168.25 million, a PE ratio of 4.40 and a beta of 1.29. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PBYI. Tower Research Capital LLC TRC lifted its stake in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 6,351 shares in the last quarter. Graham Capital Management L.P. purchased a new position in shares of Puma Biotechnology during the 4th quarter valued at $33,000. ProShare Advisors LLC purchased a new position in shares of Puma Biotechnology during the 4th quarter valued at $36,000. C2C Wealth Management LLC purchased a new position in shares of Puma Biotechnology during the 4th quarter valued at $37,000. Finally, Causeway Capital Management LLC purchased a new position in shares of Puma Biotechnology during the 1st quarter valued at $42,000. Hedge funds and other institutional investors own 61.29% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.